Inside the Lab American Society for Clinical Pathology

Women make up a majority of the workforce in pathology yet lag behind men in leadership roles. What are the consequences of this for women working in pathology today, and what can be done? In this episode of Inside the Lab, Drs. Melissa Upton and Kimberly Sanford share a warm conversation in which they reflect on their long and varied careers, describe the unique challenges they faced over their careers, and discuss their accomplishments as trailblazers themselves. Our guests descr...

Although molecular testing offers promising opportunities for diagnosis and targeted treatment of cancers, prostate cancer has lagged behind other types of cancer. Recently, homologous recombination repair testing in prostate cancer has provided a means to achieving targeted treatments for patients as well as opening new avenues of collaboration between pathologists and oncologists.On this episode of Inside the Lab, hosts Ms. Kelly Swails, MLS(ASCP), and Dr. Ali Brown, MD, FASCP are joined by...

As CRC affects younger and more diverse populations, emerging tests for CRC biomarkers provide enormous utility for diagnosis. However, misdiagnosis of CRC, shifting demographics of those afflicted with CRC, and patient unfamiliarity with symptoms create challenges in identifying CRC. In this episode of Inside the Lab, hosts Dr. Ali Brown and Lotte Mulder are joined by Dr. Melissa Taggart, a board-certified pathologist at MD Cancer Center and Karla Valencia, a laboratory manager at MD Anderso...

Recent developments in disease modifying therapies have been proven to slow the progression of cognitive decline associated with Alzheimer’s disease. And yet, we can only confirm a diagnosis of AD after a patient’s death. But what if we could use biomarkers to identify preclinical stage Alzheimer’s and step in long before a patient exhibits dementia? On this episode of Inside the Lab, your host, Ms. Kelly Swails, MT(ASCP) introduces us to Dr. Shih-Hsiu Jerry Wang, MD, PhD, Assi...

The availability of targeted therapies has changed the landscape of cancer treatment in the last few years. And two types of cancer particularly affected by these advances are melanoma and non-small cell lung carcinoma or NSCLC. What role does the laboratory play in the diagnosis and treatment of these cancers? How can pathologists and lab professionals work with oncologists to optimize biomarker testing and improve patient outcomes? On this episode of Inside the Lab, your hosts, ...

Tests that are designed in-house to fulfill a clinical need (but aren’t FDA approved) qualify as laboratory developed tests. And these LDTs are currently regulated by CLIA. But the FDA is proposing a new rule that would give them oversight of the design and development of laboratory developed tests. So, what does that mean for us? How would this new legislation impact everyday practice inside the lab? On this episode of the podcast, your hosts, Ms. Kelly Swails, MLS(ASCP), and Dr. Ali Br...